Vol. 5 No. 10 (2025)
Reimbursement Recommendations

Belantamab Mafodotin (Blenrep), Bortezomib, Dexamethasone

decorative image of the issue cover

Published October 29, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Blenrep in combination with bortezomib and dexamethasone be reimbursed by public drug plans for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, if certain conditions are met.
  • Blenrep in combination with bortezomib and dexamethasone should only be covered to treat adult patients with relapsed or refractory multiple myeloma who are in relatively good health and have already tried at least 1 other treatment for this disease. Blenrep in combination with bortezomib and dexamethasone should not be reimbursed in patients who were previously treated with an anti-BCMA therapy, patients who have experienced intolerance to bortezomib, or patients whose disease is refractory to bortezomib.
  • Blenrep in combination with bortezomib and dexamethasone should only be reimbursed if it is prescribed under the care of clinicians with expertise in the diagnosis and management of patients with multiple myeloma, and if the cost of Blenrep in combination with bortezomib and dexamethasone is reduced.